OPEN END TURBO OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 09:38:15 2024-07-08 EDT | ||
| 2.51 EUR / 2.55 EUR | -4.89% |
|
| Current month | -7.96% | ||
| 1 month | +44.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-08 | 2.49 | -6.39% |
| 24-07-05 | 2.66 | -7.32% |
| 24-07-04 | 2.87 | -2.38% |
| 24-07-03 | 2.94 | +13.08% |
| 24-07-02 | 2.6 | -8.13% |
Delayed Quote Börse Stuttgart
Last update July 08, 2024 at 05:17 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JB4JA2 |
| ISIN | DE000JB4JA25 |
| Date issued | 2023-10-16 |
| Strike | 501.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 12.79 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.57 € |
|---|---|
| Lowest since issue | 1.64 € |
| Spread | 0.3 € |
| Spread % | 10.17% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
474.6
USD
Average target price
468.3
USD
Spread / Average Target
-1.33%
- Stock Market
- Certificates
- Certificat
